Apr 20, 2026 06:45AM
Apr 20, 2026 06:45AM
Oct 21, 2025 07:30PM
Oct 21, 2025 07:30PM
May 30, 2024 10:30PM
Jan 8, 2024 06:30PM
Nov 30, 2023 05:00PM Seagen (SGEN) Announces FDA Grants Priority Review for sBLA of PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer
Nov 30, 2023 05:00PM
Aug 23, 2023 06:45AM
Aug 10, 2023 08:35AM
Jul 6, 2023 02:00AM
Apr 30, 2023 09:24PM
Apr 30, 2023 07:00PM
Apr 30, 2023 07:00PM Astellas Enters into Definitive Agreement to Acquire Iveric Bio
Feb 19, 2023 06:30PM
Dec 20, 2022 06:45AM
Dec 20, 2022 06:45AM
Aug 18, 2022 02:30AM
Jan 6, 2021 08:00AM
Oct 14, 2020 07:08AM
Oct 14, 2020 07:00AM FibroGen to Present New Efficacy and Safety Analyses from Roxadustat Global Phase 3 Program at American Society of Nephrology Kidney Week 2020 Reimagined
Dec 2, 2019 08:04AM
Dec 2, 2019 08:00AM
Dec 2, 2019 08:00AM
Sep 16, 2019 08:00AM
Sep 16, 2019 08:00AM
Aug 21, 2019 02:00PM
Aug 21, 2019 02:00PM U.S. FDA Grants XTANDI® (enzalutamide) Application Priority Review for the Treatment of Men with Metastatic Hormone-Sensitive Prostate Cancer
May 29, 2018 08:00AM
Mar 19, 2018 04:16PM
Mar 19, 2018 04:15PM
Mar 19, 2018 04:15PM
Sep 12, 2017 10:00PM
Feb 22, 2016 04:10PM
Feb 22, 2016 04:10PM FDA Accepts For Review Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in Metastatic Castration-resistant Prostate Cancer with Data from Head-to-Head Studies of Enzalutamide Ver

15,435 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All